View an enhanced version of our Special Meeting Proxy Statement.
You must register by June 14, 2023 at 5:00 PM ET to participate in the meeting.
Prometheus Biosciences is a biotech company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic product candidates. While our initial focus was on IBD, we're now extending beyond gastrointestinal (GI) diseases to target other autoimmune diseases.
Prometheus360TM, our powerful precision medicine platform, combines proprietary technology with the world's most comprehensive collection of IBD patient data, to translate deep, complex data into precision therapeutic and diagnostic product candidates and continually identify new drug targets and unique disease biomarkers. We're headquartered in San Diego, CA.